Continuous theta burst stimulation over right cerebellum for speech impairment in Parkinson’s disease: study protocol for a randomized, sham-controlled, clinical trial

Frontiers in Aging Neuroscience

Neuroscience

Ling Chen¹  Meng Wang²  Xiaoxia Zhu³  Guangyan Dai³  Xi Chen³  Zhiqin Xu³  Mingdan Tan³  Yongxue Li³  Di Lei³  Hanjun Liu⁴ 

[1] Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;Guangdong Provincial Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China;

关键词: Parkinson’s disease;    hypokinetic dysarthria;    cerebellum;    continuous theta burst stimulation;    auditory-vocal integration;   

DOI  :  10.3389/fnagi.2023.1215330

 received in 2023-05-01, accepted in 2023-08-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundSpeech impairment is a common symptom of Parkinson’s disease (PD) that worsens with disease progression and affects communication and quality of life. Current pharmacological and surgical treatments for PD have inconsistent effects on speech impairment. The cerebellum is an essential part of sensorimotor network that regulates speech production and becomes dysfunctional in PD. Continuous theta-burst stimulation (cTBS) is a non-invasive brain stimulation technique that can modulate the cerebellum and its connections with other brain regions.ObjectiveTo investigate whether cTBS over the right cerebellum coupled with speech-language therapy (SLT) can improve speech impairment in PD.MethodsIn this randomized controlled trial (RCT), 40 patients with PD will be recruited and assigned to either an experimental group (EG) or a control group (CG). Both groups will receive 10 sessions of standard SLT. The EG will receive real cTBS over the right cerebellum, while the CG will receive sham stimulation. Blinded assessors will evaluate the treatment outcome at three time points: pre-intervention, post-intervention, and at a 12-week follow-up. The primary outcome measures are voice/speech quality and neurobehavioral parameters of auditory-vocal integration. The secondary outcome measures are cognitive function, quality of life, and functional connectivity determined by resting-state functional magnetic resonance imaging (fMRI).SignificanceThis trial will provide evidence for the efficacy and safety of cerebellar cTBS for the treatment of speech impairment in PD and shed light on the neural mechanism of this intervention. It will also have implications for other speech impairment attributed to cerebellar dysfunctions.Clinical trial registrationwww.chictr.org.cn, identifier ChiCTR2100050543.

【 授权许可】

Unknown   
Copyright © 2023 Zhu, Dai, Wang, Tan, Li, Xu, Lei, Chen, Chen and Liu.

【 图 表 】

fendo-14-1154561-i003.tif

fnagi-15-1215330-i001.jpg